EX-99.1 2 q2pressrelease.htm EX-99.1 Document
image.jpg
Omada Health Reports Second Quarter 2025 Results
Revenue of $61 million, up 49%
52% Member Growth and Significant Progress Toward Profitability

SAN FRANCISCO - August 7, 2025 - Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025.

2025 Second Quarter Highlights
•Total Members of 752,000, up 52% compared to the second quarter of 2024
•Revenue of $61 million, up 49% compared to the second quarter of 2024
•GLP-1 Companion Success, with strong growth in members being supported by Omada’s GLP-1 companion programs - now available through two of the largest pharmacy benefit managers in the United States
•Omada Horizon Day: In May, Omada announced a new AI-agent, OmadaSpark, designed to deliver real-time motivational interviewing and nutrition education to members

“I’m proud of our second quarter results, with 49% year-over-year revenue growth, strong margin improvements, and continued progress toward profitability,” said Sean Duffy, Co-founder and CEO of Omada Health. “We believe our Q2 performance reflects Omada’s ability to capture tailwinds in cardiometabolic care, to effectively commercialize our GLP-1 Care Track, and to leverage advances in artificial intelligence for the benefit of our members.”

Other Second Quarter 2025 Financial Highlights
•Gross Margin of 66%, up from 60% in the second quarter of 2024
•Non-GAAP Gross Margin of 68%, compared to 63% in the second quarter of 2024
•Net Loss of $5 million, compared to a net loss of $11 million in the second quarter of 2024
•Adjusted EBITDA Loss of $0.2 million compared to a loss of $6.8 million in the second quarter of 2024
•Cash and Equivalents of $223 million

Please see the Non-GAAP Financial Measures section below and reconciliations of GAAP to non-GAAP measures at the end of this press release.



Financial Outlook
For the year ending December 31, 2025, Omada expects:
•Revenue in the range of $235 million to $241 million
•Adjusted EBITDA loss in the range of $9 million to $5 million

We have not provided an outlook for net loss (GAAP) or a reconciliation of expected adjusted EBITDA to net loss (GAAP) because net loss (GAAP) on a forward-looking basis is not available without unreasonable effort due to the potential variability and complexity of the items that are excluded from adjusted EBITDA, such as interest expense and income; loss on debt extinguishment; provision for income taxes; depreciation and amortization; share-based compensation; change in fair value of warrant liabilities; amortization of intangible assets; and loss on disposal of property and equipment.

Loan Repayment

On July 31, 2025, Omada fully repaid outstanding amounts under its term loan facility and revolving line of credit, with cumulative principal and accrued interest balances of $31.0 million and $0.4 million, respectively, ahead of their contractual maturity on June 1, 2028. Upon repayment, the related credit agreement automatically terminated in accordance with its terms. The extinguishment will reduce future interest expense and eliminate related debt covenants.

Conference Call

Omada Health will host a conference call at 1:30 p.m. PT/4:30 p.m. ET today, August 7, 2025, during which management will discuss second quarter results.

Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e.

A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months.

About Omada Health

Omada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 29 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada’s scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.

The foundation of Omada’s success is a strong, vibrant work culture, which helped earn the company the distinction of becoming a certified Great Place to Work®. An industry leader,

Omada was the first virtual provider to join the Institute for Healthcare Improvement’s Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.

Great Place to Work® is the registered trademark of the Great Place to Work Institute and is used under license.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements contained in this press release include, but are not limited to, statements we make regarding relationship with PBMs and their pharmacy benefits coverage, GLP-1 progress, business trends, growth prospects and future financial and operating results, reduction in interest expense and elimination of debt covenants, and our financial outlook.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, macroeconomic and industry conditions and other factors. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, but are not limited to, the following: our limited operating history and ability to manage our growth effectively; our history of net losses and ability to achieve or maintain profitability; the ability of our programs to achieve and maintain market acceptance; changes in the healthcare industry and competition; the growth and success of our customers and channel partners; the number of individuals covered by our programs and the number of our programs covered by our customers; the level of member engagement in our programs; our ability to maintain and grow customer and channel partner relationships; concentration of a substantial portion of our sales among a limited number of customers and channel partners; our ability to attract new customers and channel partners and increase member enrollment from existing and new customers and channel partners; our ability to increase the size of our organization; our dependence on a limited number of third-party suppliers; the impact of seasonality on our financial results; our ability to achieve widespread brand awareness and the impact of any negative media coverage; our ability to develop and release new programs and services; cybersecurity threats; our dependence on the interoperability of our programs and connected devices with third-party devices, operating systems and applications; changes in laws or regulations or the implementation of existing laws and regulations; compliance with privacy and security laws and regulations; our and our affiliated professional entities’ compliance with healthcare regulatory laws; any modification in U.S. Food

and Drug Administration enforcement policies; our dependence on our relationships with affiliated professional entities; and other risk factors identified in our filings with the Securities and Exchange Commission (the “SEC”), including our Registration Statement on Form S-1, as filed with the SEC, and other filings we may make with the SEC in the future, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

All forward-looking statements in this press release are based only on information currently available to us and speak only as of the date on which they are made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required under applicable law.



Investor Relations Contact
Allan Kells
ir@omadahealth.com

Media Contact:
Rose Ramseth
press@omadahealth.com




Omada Health, Inc.
Consolidated Balance Sheets
(in thousands, except share and per-share amounts)
(unaudited)
June 30, 2025December 31, 2024
Assets
Current assets
Cash and cash equivalents$223,146 $76,392 
Accounts receivable, net (1)
33,287 23,417 
Inventory3,469 3,296 
Deferred commissions, current3,453 3,017 
Prepaid expenses and other current assets7,750 6,937 
Total current assets271,105 113,059 
Property and equipment, net6,484 5,625 
Operating lease right-of-use asset65 447 
Deferred commissions, non-current8,552 9,214 
Intangible assets, net3,291 4,263 
Goodwill13,240 13,240 
Other assets234 5,044 
Total assets$302,971 $150,892 
Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
Current liabilities
Accounts payable$7,403 $4,168 
Accrued expenses and other current liabilities (2)
25,060 29,840 
Operating lease liability, current- 415 
Deferred revenue (3)
25,525 19,530 
Total current liabilities57,988 53,953 
Long term debt29,966 29,771 
Warrant liabilities, non-current430 2,252 
Other liabilities, non-current373 285 
Total liabilities88,757 86,261 
Commitments and contingencies
Redeemable convertible preferred stock, $0.001 par value per share; no shares and 120,689 shares authorized as of June 30, 2025 and December 31, 2024, respectively; no shares and 118,219 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively, net of issuance costs- 449,034 
Stockholders' equity (deficit)
Common stock, $0.001 par value per share; 750,000 and 181,500 shares authorized as of June 30, 2025 and December 31, 2024, respectively; 57,321 and 8,157 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively56 8 
Additional paid-in capital672,883 59,555 
Accumulated deficit(458,725)(443,966)
Total stockholders' equity (deficit)214,214 (384,403)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)$302,971 $150,892 

(1)Includes amounts from a related party of $15.1 million and $13.2 million as of June 30, 2025 and December 31, 2024, respectively.
(2)Includes amounts from a related party of $3.9 million and $2.2 million as of June 30, 2025 and December 31, 2024, respectively.
(3)Includes amounts from a related party of $18.7 million and $13.2 million as of June 30, 2025 and December 31, 2024, respectively.

Omada Health, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per-share data)
(unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Revenue
Services (1)
$56,960 $38,351 $106,456 $70,255 
Hardware (2)
4,411 2,861 9,878 6,052 
Total revenue61,371 41,212 116,334 76,307 
Cost of revenue- 
Services (3)
12,673 10,759 25,417 21,055 
Hardware8,392 5,619 18,711 13,070 
Total cost of revenue21,065 16,378 44,128 34,125 
Gross profit40,306 24,834 72,206 42,182 
Operating expenses
Research and development (4)
10,024 8,987 18,830 17,883 
Sales and marketing (5)
22,318 15,191 42,488 32,387 
General and administrative (6)
12,308 10,693 23,628 19,942 
Total operating expenses44,650 34,871 84,946 70,212 
Operating loss(4,344)(10,037)(12,740)(28,030)
Other expense, net- 
Interest expense1,094 1,132 2,168 2,262 
Interest income(863)(85)(1,405)(614)
Change in fair value of warrant liabilities736 (392)1,256 (17)
Total other expense, net967 655 2,019 1,631 
Loss before provision for income taxes(5,311)(10,692)(14,759)(29,661)
Provision for income taxes- - - - 
Net loss and comprehensive loss$(5,311)$(10,692)$(14,759)$(29,661)
Net loss per share - basic and diluted$(0.24)$(1.40)$(0.98)$(3.92)
Weighted-average shares outstanding - basic and diluted21,9717,64915,1077,571

(1)Includes amounts from a related party of $36.5 million and $21.2 million for the three months ended June 30, 2025 and 2024, respectively and $66.4 million and $38.6 million for the six months ended June 30, 2025 and 2024, respectively.
(2)Includes amounts from a related party of $2.6 million and $1.5 million for the three months ended June 30, 2025 and 2024, respectively and $6.0 million and $3.0 million for the six months ended June 30, 2025 and 2024, respectively.
(3)Includes amounts from a related party of $1.2 million and $0.8 million for the three months ended June 30, 2025 and 2024, respectively and $2.4 million and $1.7 million for the six months ended June 30, 2025 and 2024, respectively.
(4)Includes amounts from a related party of $0.5 million and $0.4 million for the three months ended June 30, 2025 and 2024, respectively and $1.0 million and $0.8 million for the six months ended June 30, 2025 and 2024, respectively.
(5)Includes amounts from a related party of $6.6 million and $3.6 million for the three months ended June 30, 2025 and 2024, respectively and $12.2 million and $7.2 million for the six months ended June 30, 2025 and 2024, respectively.
(6)Includes amounts from a related party of $0.4 million and $0.2 million for the three months ended June 30, 2025 and 2024, respectively and $0.7 million and $0.5 million for the six months ended June 30, 2025 and 2024, respectively.


Omada Health, Inc.
Share-based Compensation Summary
(in thousands)
(unaudited)

Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
Services cost of revenue$33 $53 $71 $105 
Research and development528 465 1,023 797 
Sales and marketing884 635 1,614 1,367 
General and administrative1,385 926 2,966 2,679 
Total share-based compensation expense$2,830 $2,079 $5,674 $4,948 



Omada Health, Inc.
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

Six Months Ended June 30,
20252024
Operating activities
Net loss$(14,759)$(29,661)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization2,685 2,296 
Share-based compensation5,674 4,948 
Loss on disposal of property and equipment2 1 
Amortization of debt issuance costs252 193 
Non-cash operating lease expense382 358 
Change in fair value of warrants1,256 (17)
Provision for credit losses (1)
490 489 
Amortization of deferred commissions1,561 1,208 
Changes in operating assets and liabilities
Accounts receivable (2)
(10,360)(9,834)
Inventory(173)1,487 
Prepaid expenses and other current assets(870)(495)
Deferred commissions(1,423)(3,661)
Other non-current assets118 210 
Accounts payable1,016 (1,170)
Operating lease liabilities(415)(381)
Accrued expenses and other current liabilities (3)
(4,780)(3,061)
Deferred revenue (4)
5,995 8,252 
Other non-current liabilities89 90 
Net cash used in operating activities(13,260)(28,748)
Investing activities
Purchases of property and equipment(586)(336)
Capitalized internal-use software costs(1,913)(1,490)
Net cash used in investing activities(2,499)(1,826)
Financing activities
Proceeds from exercise of stock options3,908 1,379 
Payment of deferred offering costs(1,927)(2,277)
Proceeds from initial public offering, net of underwriting discounts and commissions160,532 - 
Net cash provided by (used in) financing activities162,513 (898)
Net increase (decrease) in cash and cash equivalents146,754 (31,472)
Cash and cash equivalents at beginning of period76,392 115,643 
Cash and cash equivalents at end of period$223,146 $84,171 
(1)Includes changes in related party balances of $(0.3) million and $0.1 million for the six months ended June 30, 2025 and 2024, respectively.
(2)Includes changes in related party balances of $1.9 million and $5.5 million for the six months ended June 30, 2025 and 2024, respectively.
(3)Includes changes in related party balances of $1.7 million and $0.8 million for the six months ended June 30, 2025 and 2024, respectively.
(4)Includes changes in related party balances of $5.5 million and $5.8 million for the six months ended June 30, 2025 and 2024, respectively.

Non-GAAP Financial Measures

We use certain financial measures not calculated in accordance with accounting principles generally accepted in the United States (“GAAP”) to supplement the financial information in our consolidated financial statements, which are presented in accordance with GAAP. These non-GAAP financial measures include non-GAAP gross profit, non-GAAP gross margin, adjusted EBITDA, adjusted EBITDA margin, and free cash flow.

We define non-GAAP gross profit and non-GAAP gross margin as gross profit and gross margin, excluding share-based compensation expense, amortization of intangible assets, and depreciation and amortization.

We define adjusted EBITDA as net loss and comprehensive loss reported on our consolidated statements of operations, excluding the impact of interest expense, interest income, change in fair value of warrant liabilities, loss on debt extinguishment, provision for income taxes, share-based compensation expense, amortization of intangible assets, depreciation and amortization, and loss on disposal of property and equipment.

Free cash flow is net cash used in operating activities less purchases of property and equipment and capitalized internal-use software costs.

We believe these non-GAAP financial measures, when taken collectively with GAAP financial information, are useful to investors and others because they allow for additional information with respect to financial measures used by management in its financial and operational decision-making. However, there are a number of limitations related to the use of non-GAAP financial measures. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

Key Metric

Total Members: A member is a person who is enrolled in one of our virtual care programs and that generated a billing event in the preceding 12 months. We believe growth in the number of members is a key indicator of the performance of our business for both investors and management as we monitor the performance of our business, as members primarily drive services revenue. The number of members depends, in part, on our ability to successfully market our services to new customers and channel partners, our ability to sell additional programs to existing customers and channel partners, and our ability to promote awareness of our programs among covered individuals and to encourage their enrollment.

Reconciliation of GAAP to Non-GAAP Financial Measures

The following tables reconcile to the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Omada Health, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures - Adjusted EBITDA
(in thousands)
(unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
(in thousands, except percentages)
GAAP net loss and comprehensive loss$(5,311)$(10,692)$(14,759)$(29,661)
Add:
Interest expense1,094 1,132 2,168 2,262 
Interest income(863)(85)(1,405)(614)
Change in fair value of warrant liabilities736 (392)1,256 (17)
Provision for income taxes— — — — 
Share-based compensation expense2,830 2,079 5,674 4,948 
Amortization of intangible assets470 502 972 1,004 
Depreciation and amortization(1)
882 669 1,713 1,292 
Loss on disposal of property and equipment1 1 2 1 
Adjusted EBITDA$(161)$(6,786)$(4,379)$(20,785)
GAAP net loss and comprehensive loss margin (as a percentage of revenue)(8.7)%(25.9)%(12.7)%(38.9)%
Adjusted EBITDA margin (as a percentage of revenue)(0.3)%(16.5)%(3.8)%(27.2)%
(1) Depreciation and amortization includes depreciation of property and equipment and amortization of capitalized internal-use software costs


Omada Health, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
(in thousands)
(unaudited)
Three Months Ended June 30,Six Months Ended June 30,
2025202420252024
(in thousands, except percentages)
GAAP gross profit$40,306 $24,834 $72,206 $42,182 
Add:
Share-based compensation expense33 53 71 105 
Amortization of intangible assets439 439 878 878 
Depreciation and amortization(1)
786 568 1,527 1,100 
Non-GAAP gross profit41,564 25,894 74,682 44,265 
GAAP gross margin (as a percentage of revenue)65.7%60.3%62.1%55.3%
Non-GAAP gross margin (as a percentage of revenue)67.7%62.8%64.2%58.0%



GAAP Research and development expense$10,024 $8,987 $18,830 $17,883 
Less:
Share-based compensation expense528 465 1,023 797 
Depreciation and amortization (1)20 22 38 41 
Non-GAAP research and development expense$9,476 $8,500 $17,769 $17,045 
Non-GAAP research and development expense (as a % of revenue)15 %21 %15 %22 %
GAAP Sales and marketing expense$22,318 $15,191 $42,488 $32,387 
Less:
Share-based compensation expense884 635 1,614 1,367 
Amortization of intangible assets31 63 94 126 
Depreciation and amortization (1)29 31 56 58 
Non-GAAP sales and marketing expense$21,374 $14,462 $40,724 $30,836 
Non-GAAP sales and marketing expense (as a % of revenue)35 %35 %35 %40 %
GAAP General and administrative expense$12,308 $10,693 $23,628 $19,942 
Less:
Share-based compensation expense1,385 926 2,966 2,679 
Depreciation and amortization (1)47 48 92 93 
Loss on disposal of property and equipment1 1 2 1 
Non-GAAP general and administrative expense$10,875 $9,718 $20,568 $17,169 
Non-GAAP general and administrative expense (as a % of revenue)18 %24 %18 %22 %
GAAP operating expense$44,650 $34,871 $84,946 $70,212 
Less:
Share-based compensation expense2,796 2,026 5,602 4,843 
Amortization of intangible assets31 63 94 126 
Depreciation and amortization (1)96 101 186 192 
Loss on disposal of property and equipment1 1 2 1 
Non-GAAP operating expense$41,726 $32,680 $79,062 $65,050 
GAAP operating expense (as a % of revenue)72.8 %84.6 %73.0 %92.0 %
Non-GAAP operating expense (as a % of revenue)68.0 %79.3 %68.0 %85.2 %






Omada Health, Inc.
Reconciliation of GAAP Net Cash Provided by Operating Activities to Free Cash Flow
(in thousands)
(unaudited)
Six Months Ended June 30,
20252024
Net cash used in operating activities$(13,260)$(28,748)
Purchases of property and equipment(586)(336)
Capitalized internal-use software development costs(1,913)(1,490)
Free Cash Flow$(15,759)$(30,574)
Other cash flow components:
Net cash used in investing activities$(2,499)$(1,826)
Net cash used in (provided by) financing activities$162,513 $(898)